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Abstract Essential biological systems employ self-correcting mechanisms to maintain cellular
homeostasis. Mammalian cell function is dynamically regulated by the interaction of cell surface
galectins with branched N-glycans. Here we report that N-glycan branching deficiency triggers the
Golgi to generate bioequivalent N-glycans that preserve galectin-glycoprotein interactions and
cellular homeostasis. Galectins bind N-acetyllactosamine (LacNAc) units within N-glycans initiated
from UDP-GlcNAc by the medial-Golgi branching enzymes as well as the trans-Golgi poly-LacNAc
extension enzyme b1,3-N-acetylglucosaminyltransferase (B3GNT). Marginally reducing LacNAc
content by limiting N-glycans to three branches results in T-cell hyperactivity and autoimmunity; yet
further restricting branching does not produce a more hyperactive state. Rather, new poly-LacNAc
extension by B3GNT maintains galectin binding and immune homeostasis. Poly-LacNAc extension is
triggered by redistribution of unused UDP-GlcNAc from the medial to trans-Golgi via inter-cisternal
tubules. These data demonstrate the functional equivalency of structurally dissimilar N-glycans and
suggest a self-correcting feature of the Golgi that sustains cellular homeostasis.
DOI: 10.7554/eLife.14814.001
Introduction
Self-correcting mechanisms have evolved to maintain the integrity of critical biological pathways in
the face of disruptive insults and stochastic uncertainty. Such mechanisms range from proofreading
in DNA replication to functional redundancy of important cellular apparatuses. The galectin-glyco-
protein lattice is a dynamic cell surface structure that globally regulates receptor localization and sig-
naling (Demetriou et al., 2001; Partridge et al., 2004; Lau et al., 2007; Dennis et al., 2009;
Grigorian et al., 2009). Its importance is underscored by its role in basic cellular processes such as
signaling, apoptosis, endocytosis, differentiation, and cell growth, as well as its association with a
wide range of diseases including immunity/autoimmunity (Demetriou et al., 2001; Lee et al., 2007;
Mkhikian et al., 2011; Li et al., 2013; Wang et al., 2015; Zhou, 2014), cancer (Dennis et al., 1987;
Fernandes et al., 1991; Granovsky et al., 2000; Beheshti Zavareh et al., 2012; Croci et al.,
2014), and Type 2 diabetes (Ohtsubo et al., 2005; Johswich et al., 2014). However, a mechanism
that homeostatically sustains the lattice is not known.
The lattice forms due to the multivalent interactions between extracellular galectins, a family of
sugar binding proteins, and the disaccharide N-acetyllactosamine (LacNAc) present on Asn (N)-
linked glycans attached to cell surface glycoproteins (Hirabayashi et al., 2002; Brewer et al., 2002;
Ahmad et al., 2004). The vast majority of secreted and cell surface proteins are co- or post-
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translationally modified by the addition of sugars in the ER. As these proteins transit through the ER
and Golgi, their glycans undergo dramatic remodeling, generating a vast and heterogeneous array
of glycoforms (Kornfeld and Kornfeld, 1985; Schachter, 1991). In the medial Golgi a group of
enzymes, MGAT1, 2, 4, and 5, act to produce N-glycans with one, two, three, or four N-
-acetylglucosamine (GlcNAc) branches (Schachter, 1986). The subsequent addition of galactose by
a family of galactosyl transferase enzymes produces the galectin substrate LacNAc (Figure 1—figure
supplement 1A). The number of branches depends on the relative activity of the medial Golgi
branching enzymes MGAT1, 2, 4, and 5 and the availability of their shared donor substrate UDP-
GlcNAc (Lau et al., 2007; Dennis et al., 2009; Grigorian et al., 2007; 2011). Alternating action of
b1,3-N-acetylglucosaminyltransferase (B3GNT) and galactosyl transferase enzymes can generate a
linear polymer of LacNAc (poly-LacNAc) at any given branch. Although the affinity of galectin bind-
ing to a LacNAc monomer is relatively weak, increased LacNAc valency through branching and poly-
LacNAc extension can dramatically increase galectin avidity leading to a major impact on cell surface
dynamics (Hirabayashi et al., 2002). In T cells for example, galectin - T cell receptor (TCR) interac-
tions directly oppose ligand induced TCR clustering and signaling, thereby negatively regulating T
cell development, antigen-dependent T cell growth, and autoimmunity risk.
Glycan analysis of tissues from glycosylation pathway deficient mice has revealed the presence of
minor but unusual structures (Stone et al., 2009; Takamatsu et al., 2010; Ismail et al., 2011). The
function of these changes is unclear, but some have suggested that the observed structural altera-
tions may reflect production of bioequivalent glycans that are induced by communication between
the cell surface and the Golgi (Takamatsu et al., 2010; Dam and Brewer, 2010; Dennis and
Brewer, 2013). However, direct evidence supporting this possibility is lacking. Deficiency in the
branching enzyme b1,6-N-acetylglucosaminyltransferase V (MGAT5) reduces avidity for galectin,
eLife digest Most proteins that are released from cells are modified with sugar molecules that
allow the proteins to carry out their role properly. These modifications are called glycans, and are
made from sugar subunits joined into chains or branched structures. Investigating how the structure
of glycans is linked to their role is complicated by the fact that many different glycans exist, made
up of different sugars and arranged into different structures.
Enzymes located in cell compartments known as the endoplasmic reticulum and the Golgi help to
build the glycans. For example, the MGAT family of enzymes found in the Golgi generates branched
glycans made up of sugar subunits called N-acetyllactosamine (LacNAc). These glycans form part of
a molecular mesh on the surface of cells that controls how certain proteins embedded in the cell
membrane behave. This is particularly important in immune cells: reducing the number of branches
in the glycans weakens the mesh and causes the cells and their membrane proteins to behave
inappropriately.
Mkhikian et al. have studied mice that lack specific MGAT enzymes, and so produce LacNAc
glycans with drastically fewer branches than normal. Immune cells in these mice had glycans on their
surface formed of LacNAc arranged in chains, rather than in short branched structures. These chains
turned out to be biologically equivalent to branched LacNAc glycans, containing the same sugar
subunits and allowing the immune cells to behave as normal. This suggests that the composition of
glycans, rather than their structure, primarily determines their role.
Mkhikian et al. also found that the organization of the enzymes inside the Golgi is likely to be
responsible for producing these equivalent glycans. A glycan is built up as it passes through the
Golgi, with the branching enzymes located earlier in the Golgi than the extending enzymes.
Therefore, if the branching enzymes fail to add LacNAc subunits to the glycan, the extending
enzymes can step in later to add the missing components.
Overall, the results presented by Mkhikian et al. indicate that the large number of structurally
diverse glycans may be reduced to a much smaller number of glycans with similar roles, based on
subunit composition. This will simplify future studies on LacNAc glycans, and further work could
focus on defining which other glycan structures share similar roles.
DOI: 10.7554/eLife.14814.002
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Figure 1. Compensation limits hyperactivity of Mgat2 deficient T cells. (A, B, D and E) T cells were activated with plate bound anti-CD3 for 24 (A and D)
or 72 (B and E) hours. CD4+ (A and B) or CD8+ (D and E) cells were analyzed for CD69 expression (A and D) or 5, 6-carboxyfluorescein diacetate
Figure 1 continued on next page
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enhancing antigen dependent and independent TCR clustering/signaling, leading to development
of spontaneous autoimmune disease (Demetriou et al., 2001; Lee et al., 2007). Based on the cur-
rent model of the galectin-glycoprotein lattice, more severe reductions in branching should weaken
the lattice further and result in greater T cell hyperactivity. Surprisingly, further limiting branching
revealed that the Golgi apparatus has a remarkable capacity to buffer challenges to the strength of
the galectin-glycoprotein lattice. Our analysis reveals a homeostatic mechanism built into the archi-
tecture of the Golgi apparatus that induces bioequivalent poly-LacNAc glycans that act to maintain
the function of the galectin-glycoprotein lattice in the face of dysregulated Golgi branching.
Results
Mgat2 deficiency does not increase T cell hyperactivity beyond Mgat5
deficiency
To further investigate the role of branching in T cells, we generated T cell specific Mgat2 deficient
mice (Mgat2f/f::Lck-Cre+) (Ye and Marth, 2004). Loss of Mgat2 is expected to limit N-glycans to a
single branch, producing hybrid structures; although a second branch via MGAT4 activity is possible
(Figure 1—figure supplement 1A). As the branching pathway declines in enzymatic efficiency going
from MGAT1 to MGAT5, Mgat2 deficiency also impacts a much greater percentage of cell surface
glycans than Mgat5 deletion (Wang et al., 2001). Examination of peripheral T cells from Mgat2f/f::
Lck-Cre+ mice indicated loss of Mgat2 in most but not all T cells as assayed by flow cytometry with
the plant lectin L-PHA (Phaseolus vulgaris, leukoagglutinin) (Figure 1—figure supplement 1B).
b1,6GlcNAc-branched N-glycans produced by MGAT5 specifically bind L-PHA, structures that are
also lost following Mgat2 deletion (Demetriou et al., 2001; Cummings and Kornfeld, 1982). Sur-
prisingly, Mgat5 and Mgat2 deficient CD4+ and CD8+ T cells displayed a similar degree of activation
and proliferation in response to anti-CD3 (an antibody which induces TCR clustering and signaling)
despite the more dramatic reduction in LacNAc branching in Mgat2 deficient T cells (Figure 1A,B,D
and E). This suggested that either the b1,6GlcNAc branch produced by the MGAT5 enzyme is
uniquely important for regulating T cell activation or that a compensatory mechanism maintains
galectin binding when the number of LacNAc branches is reduced. To evaluate for potential differ-
ences in total surface LacNAc content between Mgat2 and Mgat5 deficient T cells, galectin-3 bind-
ing at the cell surface was measured by flow cytometry. Mgat5 deletion resulted in a significant
reduction in the ability of CD4+ and CD8+ T cells to bind galectin-3 (Figure 1C and F), consistent
with previously published results (Demetriou et al., 2001). However, Mgat2 deficiency produced no
additional decrease in galectin-3 binding (Figure 1C and F), suggesting comparable LacNAc content
at the cell surface despite a marked reduction in LacNAc branches in Mgat2 relative to Mgat5 defi-
cient T cells.
Inhibition of LacNAc branching results in linear extension with poly-
LacNAc
Since the branching pathway enzymes act sequentially, we hypothesized that compensatory mainte-
nance of cell surface LacNAc content in Mgat2 deficient T cells would primarily occur by poly-Lac-
NAc extension of the MGAT1 generated branch (Figure 1—figure supplement 1A). To test this
Figure 1 continued
succinimidyl ester (CFSE) dilution (B and E) by flow cytometry, gating on L-PHA- cells where indicated. (C and F) T cells were analyzed for galectin-3
binding by flow cytometry, gating on CD4+ (C) or CD8+ (F) cells and L-PHA- cells where indicated. Normalized geometric mean fluorescence intensity
(MFI) is shown. Each mutant was normalized to its control. (G) Thymocytes and splenic T cells were analyzed for L-PHA and LEA binding by flow
cytometry. (H) Cells were treated in culture with or without 500 nM SW for 72 hr followed by analysis of LEA binding by flow cytometry. Fold increase in
LEA MFI of the SW treated sample compared to the untreated sample is presented. The red line marks one fold or no change. NS, not significant;
*p<0.05; **p<0.01; ***p<0.001 (unpaired two-tailed t-test with Welch’s (C, F and H) and Bonferroni correction (C and F)). Data show one experiment
representative of at least three independent experiments. Error bars indicate mean ± s.e.m.
DOI: 10.7554/eLife.14814.003
The following figure supplement is available for figure 1:
Figure supplement 1. The hexosamine and N-glycan biosynthetic pathways in mammals.
DOI: 10.7554/eLife.14814.004
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Figure 2. Branching deficiency induces poly-LacNAc on N-glycans. (A) Thymocytes were analyzed for L-PHA and LEA binding by flow cytometry, gating
on CD4+CD8+ double positive cells. (B and C) CHO and Lec1 cells were grown in the presence or absence of 500 nM SW for 3 days followed by
Figure 2 continued on next page
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prediction, T cells and thymocytes were stained with L-PHA as well as the Lycopersicon Esculentum
lectin (LEA). LEA binds to poly-LacNAc structures containing at least three repeating LacNAc units
(Kawashima et al., 1990; Merkle and Cummings, 1987). Wild type and Mgat5-/- T cells and thymo-
cytes expressed very low levels of poly-LacNAc. However, in Mgat2f/f::Lck-Cre+ mice, loss of L-PHA
staining was accompanied by a ~100 fold increase in LEA staining. The loss of L-PHA binding and
the increase in LEA binding appeared to occur concurrently during the double positive stage of thy-
mocyte development, shortly after the Lck promoter driven Cre is first expressed, and were main-
tained through the single positive stage and in peripheral T cells (Figure 1G). Treatment of various
cell types with swainsonine (SW), a mannosidase II inhibitor which blocks N-glycan processing
between MGAT1 and MGAT2 (Figure 1—figure supplement 1A), indicated that homeostatic up-
regulation of poly-LacNAc was a general feature of many cell types including epithelial, mesenchy-
mal, and hematopoietic cells; with the greatest responses in the latter (Figure 1H).
Poly-LacNAc may occur on N-glycans as well as O-glycans and glycolipids (Fukuda et al., 1986;
Watanabe et al., 1979). Furthermore, LEA has been reported to bind to high-mannose structures in
addition to poly-LacNAc (Oguri, 2005). To investigate the structural basis for the increase in LEA
staining, Mgat2 deficient T cells were treated with PNGase F, an amidase which specifically cleaves
N –glycans (Maley et al., 1989). PNGase F treatment of live cells incompletely removes N-glycans,
with a four hour treatment of Mgat2f/f T cells reducing cell surface L-PHA binding by ~50% (Fig-
ure 2—figure supplement 1A–B). Nevertheless, the same treatment resulted in a >80% reduction in
LEA binding in Mgat2 deficient T cells, suggesting that the vast majority of LEA staining was due to
cell surface N-glycans (Figure 2—figure supplement 1C–D). To further evaluate this question, we
directly compared thymocytes derived from Mgat2f/f::Lck-Cre+ and Mgat1f/f::Lck-Cre+ mice
(Zhou, 2014). Mgat1 deficiency blocks all branching and poly-LacNAc extension in N-glycans, but
not O-glycans or glycolipids. Indeed, unlike Mgat2 deficiency, Mgat1 deficient thymocytes do not
show an increase in LEA staining concurrent with the loss in L-PHA staining (Figure 2A). Similarly,
SW increases LEA staining in CHO cells but not Mgat1 deficient CHO (Lec1) cells (Figure 2B and C).
Furthermore, increased LEA staining induced by SW treatment of T cells was reversed by the manno-
sidase I inhibitors deoxymannojirimycin (DMN) and kifunensine (kif), which block the N-glycan path-
way prior to MGAT1 (Figure 2D).
Poly-LacNAc content was also investigated using mass spectrometric glycomic methodologies.
SW treated Jurkat cells, rather than T cells from Mgat2f/f::Lck-Cre+ mice, were used for this purpose
to provide a sufficient amount of starting material for accurate analysis. MALDI-TOF-MS of N-glycans
Figure 2 continued
analysis for L-PHA (B) or LEA (C) binding by flow cytometry. (D) Resting primary human T cells were treated as indicated for 3 days and analyzed for
L-PHA (upper) or LEA (lower) binding by flow cytometry, gating on live, non-blasting CD4+ cells. (E-–G) MALDI-TOF analysis of Sialidase A (E) or Endo-
b-galactosidase treated N-glycans from Jurkat T cells treated without (F) or with SW (E and G). Hybrid glycans with extended antennae were observed
in (E) at m/z 2897, 3102, 3347, 3551 and 4000, which are highlighted with red arrows. The % intensities of the peaks in (F, G) are shown in the brackets
after m/z values. The signals at m/z 518, 722 and 1084 are derived from linear poly-LacNAc antennae and are used to represent the length of antennae.
The calculation is shown above the spectrum. In addition, a minority of non-sialylated poly-LacNAc antennae were found to be internally fucosylated
yielding GlcNAcb1,3Galb1,4(Fuca1,3)GlcNAcb1,3Gal (m/z 1142) and Galb1,4GlcNAcb1,3Galb1,4(Fuca1,3)GlcNAcb1,3Gal (m/z 1346) upon digestion.
MS/MS analysis of the peaks at m/z 1142 and 1346 also revealed the presence of isobaric pauci-mannose glycans, their relative abundances are
indicated on the figure (see Figure 2—figure supplement 3). Ions are in the form of M+Na+. Peaks are annotated with putative structures according to
the molecular weight, the glycan biosynthetic pathway and for (E), the MALDI-TOF analysis of the N-glycans before Sialidase A treatment (shown in
Figure 2—figure supplement 2). NS, not significant; **p<0.01; ***p<0.001 (unpaired two-tailed t-test with Welch’s (B–D) and Bonferroni correction
(D)). Data show one experiment representative of at least three independent experiments (A–D), except mass spectrometry (E–G), which was performed
once. Error bars indicate mean ± s.e.m.
DOI: 10.7554/eLife.14814.005
The following figure supplements are available for figure 2:
Figure supplement 1. Induction of poly-LacNAc structures occurs preferentially on N-glycans.
DOI: 10.7554/eLife.14814.006
Figure supplement 2. MALDI-TOF analysis of N-glycans from SW treated Jurkat T cells MALDI-TOF analysis of N-glycans from SW treated Jurkat T
cells.
DOI: 10.7554/eLife.14814.007
Figure supplement 3. MS/MS analysis of endo-b-galactosidase digested glycans from Jurkat T cells.
DOI: 10.7554/eLife.14814.008
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Figure 3. Poly-LacNAc compensation opposes T cell activation and autoimmunity. (A) Jurkat T cells were treated as indicated for 72 hr in culture and
analyzed for galectin-3 binding by flow cytometry. (B and C) Human T cells were pre-treated as indicated for 72 hr in culture without stimulation, then
activated with plate bound anti-CD3 for 24 (B) or 72 (C) hours and analyzed for CD69 expression (B) or CFSE dilution (C) by flow cytometry, gating on
CD4+ cells. (D) Mouse T cells were analyzed for galectin-3 binding by flow cytometry, gating on CD4+ cells. Where indicated, mice were pre-treated for
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derived from SW treated Jurkat T cells confirmed the presence of hybrid N-glycans with up to two
poly-LacNAc extended branches (m/z 2897, 3102, 3347, 3551, and 4000 in Figure 2E, Figure 2—fig-
ure supplement 2). This was qualitatively consistent with the presence of poly-LacNAc following SW
treatment, but likely under-represents the length of poly-LacNAc extension due to the limited sensi-
tivity of MALDI-TOF-MS for large poly-LacNAc structures. To better quantitate the change in poly-
LacNAc, endo-b-galactosidase digestion was used. This enzyme cuts all internal Galb1,4 linkages in
poly-LacNAc structures, unless the GlcNAc on its reducing side is modified by fucose. Endo-b-galac-
tosidase digestion produced GlcNAcb1,3Gal (m/z 518) from internal linear poly-LacNAc antennae,
together with Galb1,4GlcNAcb1,3Gal (m/z 722) and NeuAc-Galb1,4GlcNAcb1,3Gal (m/z 1084) from
their non-reducing termini (Figure 2F,G and Figure 2—figure supplement 3). The ratio of the inter-
nal and terminal glycans examines the relative length of linear poly-LacNAc structures, with a higher
ratio signifying longer chains. The non-treated cells had a ratio of 0.5, which increased to 1.1 in the
SW treated cells (Figure 2F and G), confirming the presence of longer poly-LacNAc chains after SW
treatment. Mgat2 deficient T cells are expected to have a greater increase, given the ~100 fold
increase in LEA binding compared to the ~20 fold increase in SW treated Jurkat cells. Together,
these data indicate that severe LacNAc branching deficiency increases poly-LacNAc structures on
N-glycans.
Homeostatic poly-LacNAc opposes T cell hyperactivity and
autoimmunity
To assess the functional consequences of poly-LacNAc up-regulation, we first reversed SW induced
poly-LacNAc by blocking all branching using the mannosidase I inhibitors deoxymannojirimycin
(DMN) or kifunensine. Whereas SW treatment alone moderately reduced galectin-3 binding, the
addition of kifunensine dramatically reduced galectin-3 binding of Jurkat T cells (Figure 3A). As pre-
viously shown, SW treatment alone caused significant increases in both anti-CD3 induced activation
and proliferation of primary human T cells (Figure 3B,C and Figure 3—figure supplement 1). How-
ever, the addition of kifunensine or DMN resulted in much greater hyperactivity, particularly at lower
doses of anti-CD3. Careful titration of kifunensine in the presence of SW did not further reduce
L-PHA binding, yet caused a dose dependent decrease in LEA binding and increase in CD69 induc-
tion, indicating that poly-LacNAc extension dose dependently regulates T cell activation thresholds
(Figure 3—figure supplement 1A–B).
To further confirm the functional role of homeostatic induction of poly-LacNAc, mouse T cells
deficient in both Mgat2 and B3gnt2 were generated. B3GNT2 is one of the major B3GNT enzymes
responsible for poly-LacNAc branch extension in mouse T cells and poly-LacNAc up-regulation is
expected to be limited in its absence (Togayachi et al., 2007). Indeed, T cells from Mgat2f/f::Lck-
Cre+::B3gnt2-/- mice showed significantly reduced galectin-3 binding when compared to Mgat2 defi-
cient T cells, confirming reduced LacNAc content (Figure 3D). Directly comparing T cell activation
between these lines showed that both genetic and pharmacological inhibition of homeostatic poly-
LacNAc extension resulted in significantly increased T cell hyperactivity (Figure 3E).
Since the galectin lattice has been shown to inhibit autoimmunity, we next sought to determine
the functional consequences of glycomic homeostasis in regulating the course and severity of experi-
mental autoimmune encephalomyelitis (EAE), a model that mimics the autoimmune CNS pathology
Figure 3 continued
3 days with 0.2 mg/ml kifunensine in the drinking water. (E) Mouse T cells were activated for 24 hr with plate bound anti-CD3 and analyzed for CD69
expression by flow cytometry, gating on CD4+ cells. Where indicated, mice were pre-treated for 3 days with 0.2 mg/ml kifunensine in the drinking water
followed by 10 mM kifunensine during culture. (F) EAE was induced in age matched female C57BL/6 mice treated with or without kifunensine in the
drinking water at 0.2 mg/ml from day -3 to 5, with day 0 indicating the time of immunization (n = 9 per group). (G) On day 30, splenocytes were isolated
from representative mice of each EAE group and analyzed for cytokine expression by flow cytometry. NS, not significant; *p<0.05; **p<0.01; ***p<0.001
(unpaired two-tailed t-test with Welch’s (C, D and G) and Bonferroni correction (C, D and G)). Data shown are one experiment representative of at least
three independent experiments (A–E), except EAE (F and G), which was performed once. Error bars indicate mean ± s.e.m.
DOI: 10.7554/eLife.14814.009
The following figure supplement is available for figure 3:
Figure supplement 1. Poly-LacNAc compensation opposes T cell activation and autoimmunity.
DOI: 10.7554/eLife.14814.010
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Figure 4. Increased TCR signaling and UDP-GlcNAc levels are neither necessary nor sufficient for poly-LacNAc induction. (A) WT, TCRb-/- and Lck-/-
Jurkat cells were treated with SW for the indicated times and analyzed for lectin binding by flow cytometry. (B) Jurkat cells were treated as indicated for
24 hr and analyzed for LEA binding by flow cytometry. (C) Lysates of Jurkat T cells treated with SW as indicated were immune-blotted with anti-
B3GNT2 and actin. (D) B3GNT enzyme activity was measured in lysates of Jurkat T cells treated with and without SW for 72 hr. (E–G) Total cellular UDP-
GlcNAc levels were measured in mouse T cells (E), or Jurkat T cells treated as indicated (F, G) via mass spectrometry (E and G) or a spectrophotometric
method (F). Jurkat cells were treated for the indicated times (F) or for 24 hr (G). NS, not significant; *p<0.05; **p<0.01; ***p<0.001 (unpaired two-tailed
t-test with Welch’s (B, D, E and G) and Bonferroni correction (B and G)). Data show one experiment representative of at least three independent
experiments. Error bars indicate mean ± s.e.m.
Figure 4 continued on next page
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of multiple sclerosis (Grigorian et al., 2011). Mgat2f/f and Mgat2f/f::Lck-Cre+ mice were treated with
either vehicle or kifunensine in the drinking water from day -3 to 5, with day 0 indicating time of
immunization. As expected, vehicle treated Mgat2f/f::Lck-Cre+ mice displayed a significantly more
severe EAE than vehicle treated Mgat2f/f mice. However, kifunensine treatment of Mgat2f/f::Lck-
Cre+ mice resulted in a dramatic increase in clinical score and disease incidence early in the disease
course, a difference that narrowed later in the absence of kifunensine (Figure 3F and Figure 3—sup-
plement figure 1D). Kifunensine treated mice also had more pro-inflammatory TH1 and TH17 cells
compared to vehicle treated mice in vivo and following re-stimulation with MOG 35–55 in vitro
(Figure 3G, Figure 3—figure supplement 1E). Taken together these data demonstrate a major role
for homeostatic poly-LacNAc extension in controlling T cell growth, differentiation, and self-
tolerance.
Homeostatic poly-LacNAc is not induced by alterations in enzyme
activity
As the galectin-glycoprotein lattice negatively regulates TCR signaling and TCR signaling promotes
lattice strength (Demetriou et al., 2001; Chen et al., 2009), we hypothesized that LacNAc homeo-
stasis may result from a feedback loop linking TCR signaling and cell surface LacNAc content. Such a
mechanism, which depends on a cell surface sensor of Golgi activity/branching implies a temporal
lag phase during which a defect is detected, a signal is sent, and then the Golgi generates the
proper response. With this prediction in mind, Jurkat T cells were treated with SW for various times
and analyzed for changes in cell surface glycosylation by L-PHA, LEA, and Concanavalin A (ConA),
the latter a plant lectin that binds high-mannose structures increased by SW treatment (Figure 4—
figure supplement 1A–C). Although the increase in LEA binding trailed slightly behind an increase
in ConA binding, it began to increase within ~1.5 hr of SW treatment, indicating an almost immedi-
ate compensatory response. Loss of L-PHA staining exhibited the smallest slope, possibly reflecting
the preferential cell surface retention of highly branched glycoproteins (Figure 4—figure supple-
ment 1C).
Since the increase in LEA staining exhibited some delay, the role of TCR signaling in driving poly-
LacNAc induction was assessed. Blocking TCR signaling genetically, with TCRb and Lck deficient
Jurkat lines, or pharmacologically, with MAP kinase inhibitors, only partially reduced the magnitude
of the poly-LacNAc response induced by SW (Figure 4A and Figure 4—figure supplement 1D).
More importantly, directly activating downstream TCR signaling with PMA and ionomycin did not
induce poly-LacNAc up-regulation, although it further enhanced poly-LacNAc triggered by SW
(Figure 4B). Thus, TCR signaling appears to be neither necessary nor sufficient for the homeostatic
poly-LacNAc response, but does contribute to its magnitude in the context of deficient branching.
Since most surface receptors are glycosylated, there are a large number of possible additional
cell surface sensors that may alter signaling to drive compensation. However, we reasoned that
regardless of the upstream components, a mechanism that acts to increase poly-LacNAc production
must do so by either increasing the activity of responsible enzymes or increasing substrate supply
(UDP-GlcNAc or glycoprotein) for the reaction. It is unlikely that an increase in mono-antennary gly-
cans could account for the observed compensatory response, as all branches are equally likely to be
extended with poly-LacNAc (Antonopoulos et al., 2012; Ishida et al., 2005).
Microarray analysis of purified Mgat2+/+ and Mgat2-/- CD4+ T cells revealed no significant
changes in glycosylation genes known to impact poly-LacNAc production or UDP-GlcNAc biosynthe-
sis (Table 1). Gene expression was altered in some genes unrelated to glycosylation, but these are
likely related to downstream effects of Mgat2 deficiency (Table 2). Comparing B3GNT2 protein lev-
els in Jurkat T cells treated with or without SW also showed no difference (Figure 4C). Total poly-
LacNAc enzyme activity in lysates from control and SW treated Jurkat T cells also revealed no
Figure 4 continued
DOI: 10.7554/eLife.14814.011
The following figure supplement is available for figure 4:
Figure supplement 1. TCR signaling and cellular UDP-GlcNAc levels modulate the degree of poly-LacNAc induced by branching Deficiency.
DOI: 10.7554/eLife.14814.012
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Table 1. List of N-glycan branching, poly-LacNAc production, and hexosamine pathway genes.
Gene symbol Gene description p Value Fold change
Man1a mannosidase 1, alpha 0.3602 1.0628
Man1a2 mannosidase, alpha, class 1A, member 2 0.4885 -1.0551
Man1b1 mannosidase, alpha, class 1B, member 1 0.4397 -1.0627
Man1c1 mannosidase, alpha, class 1C, member 1 0.4053 1.0748
Man2a1 mannosidase 2, alpha 1 0.8150 -1.0168
Man2a2 mannosidase 2, alpha 2 0.3647 -1.0787
Man2b1 mannosidase 2, alpha B1 0.0800 -1.1350
Man2b2 mannosidase 2, alpha B2 0.6465 1.0331
Man2c1 mannosidase, alpha, class 2C, member 1 0.9826 1.0016
Mgat1 mannoside acetylglucosaminyltransferase 1 0.1005 -1.1846
Mgat2 mannoside acetylglucosaminyltransferase 2 0.0000 -27.8780
Mgat3 mannoside acetylglucosaminyltransferase 3 0.1757 1.1377
Mgat4a mannoside acetylglucosaminyltransferase 4, isoenzyme A 0.1486 -1.2068
Mgat4b mannoside acetylglucosaminyltransferase 4, isoenzyme B 0.2248 1.1345
Mgat4c mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase, isozyme C (putative) 0.5695 1.0539
Mgat5 mannoside acetylglucosaminyltransferase 5 0.4045 1.0666
Mgat5b mannoside acetylglucosaminyltransferase 5, isoenzyme B 0.1450 1.1347
B3gnt1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 1 0.5597 -1.0587
B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 0.1503 1.1219
B3gnt3 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 0.4031 1.1072
B3gnt4 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 0.2923 1.1100
B3gnt5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 0.1758 1.1742
B3gnt6 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 6 (core 3 synthase) 0.5565 1.0511
B3gnt7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 0.8028 1.0237
B3gnt8 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8 0.6157 1.0443
B3gnt9-ps UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 9, pseudogene 0.2841 1.0856
B3gntl1 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase-like 1 0.7979 -1.0241
B4galt1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 0.8003 1.0166
B4galt2 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2 0.1023 1.1487
B4galt3 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 3 0.6938 -1.0304
B4galt4 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 4 0.1378 1.1624
B4galt5 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 5 0.8380 1.0131
B4galt6 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 6 0.0645 -1.2196
B4galt7 xylosylprotein beta1,4-galactosyltransferase, polypeptide 7 (galactosyltransferase I) 0.4116 -1.0764
Gck glucokinase 0.0548 1.1856
Hk1 hexokinase 1 0.8593 1.0129
Hk2 hexokinase 2 0.4688 1.0771
Hk3 hexokinase 3 0.0236 -1.2237
Adpgk ADP-dependent glucokinase 0.4033 -1.0787
Gpi1 glucose phosphate isomerase 1 0.7826 -1.0173
Gfpt1 glutamine fructose-6-phosphate transaminase 1 0.2410 -1.0941
Gfpt2 glutamine fructose-6-phosphate transaminase 2 0.0289 1.2116
Gnpda1 glucosamine-6-phosphate deaminase 1 0.6667 -1.0364
Gnpda2 glucosamine-6-phosphate deaminase 2 0.9474 1.0054
Table 1 continued on next page
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difference (Figure 4D). Thus, increased B3GNT enzyme activity is not responsible for the homeo-
static up-regulation of poly-LacNAc induced by branching deficiency.
Homeostatic poly-LacNAc is not induced by alterations in UDP-GlcNAc
levels
Next we investigated whether increased cellular UDP-GlcNAc, the donor substrate for B3GNT
enzymes, is triggered by severe branching deficiency. Measurement of total cellular UDP-GlcNAc
levels by mass spectrometry and/or a colorimetric assay in cell lysates of purified Mgat2+/+ versus
Mgat2-/- T cells as well as Jurkat T cells treated with or without SW and kifunensine revealed no
increase from branching deficiency (Figure 4E–G). Supplementing cells with GlcNAc raises cellular
UDP-GlcNAc and branching (Lau et al., 2007; Mkhikian et al., 2011; Grigorian et al., 2007;
Grigorian et al., 2011). In contrast, treatment of Jurkat T cells with GlcNAc did not increase LEA
staining despite a 3–4 fold increase in cellular UDP-GlcNAc concentrations; although it further
enhanced SW induced poly-LacNAc extension (Figure 4F,G, and Figure 4—figure supplement 1E).
Over-expression of the three UDP-GlcNAc Golgi transporters (SLC35A3, SLC35B4, and SLC35D2)
via transfection into Jurkat T cells also did not increase LEA staining (Figure 5F). Thus, much like
TCR signaling, increased cellular UDP-GlcNAc levels are neither necessary nor sufficient to induce
homeostatic up-regulation of poly-LacNAc. Not surprisingly, poly-LacNAc induction was blocked by
4-Fluoro-GlcNAc, a drug known to inhibit poly-LacNAc production by reducing UDP-GlcNAc biosyn-
thesis (Barthel et al., 2011) (Figure 4—figure supplement 1F–G).
UDP-GlcNAc redistribution from Cis/Medial to Trans Golgi triggers
homeostatic poly-LacNAc
Glycosylation enzymes are organized in order of action from cis to trans along the secretory path-
way. The branching enzymes (i.e. MGAT1, 2, 4 and 5) are localized to the medial Golgi, while the
galactosyl transferase and B3GNT enzymes reside in the trans Golgi. The CMP-sialic acid transporter
has a relatively restricted localization within the Golgi (Zhao et al., 2006), suggesting that sugar-
nucleotide donors may be preferentially supplied to specific Golgi compartments. We hypothesized
that UDP-GlcNAc supply and associated transporters may be restricted to the cis/medial Golgi com-
partment, thus preferentially driving branching over extension. Consistent with this hypothesis, rais-
ing total cellular UDP-GlcNAc increases branching by the medial Golgi enzymes (Lau et al., 2007;
Mkhikian et al., 2011; Grigorian et al., 2007; Grigorian et al., 2011), but does not induce signifi-
cant up-regulation of poly-LacNAc extension by trans Golgi B3GNT enzymes (Figure 4F,G, and Fig-
ure 4—figure supplement 1E). This suggests that cytosolic UDP-GlcNAc lacks direct access to the
Table 1 continued
Gene symbol Gene description p Value Fold change
Gnpnat1 glucosamine-phosphate N-acetyltransferase 1 0.3646 -1.0839
Nat9 N-acetyltransferase 9 (GCN5-related, putative) 0.2253 1.0995
Pgm1 phosphoglucomutase 1 0.7697 -1.0243
Pgm2 phosphoglucomutase 2 0.7135 -1.0360
Pgm2l1 phosphoglucomutase 2-like 1 0.8036 -1.0167
Pgm3 phosphoglucomutase 3 0.6032 -1.0529
Pgm5 phosphoglucomutase 5 0.2374 1.1326
Uap1 UDP-N-acetylglucosamine pyrophosphorylase 1 0.6555 1.0402
Uap1l1 UDP-N-acteylglucosamine pyrophosphorylase 1-like 1 0.2637 -1.1092
Nagk N-acetylglucosamine kinase 0.2907 -1.1126
Gale galactose-4-epimerase, UDP 0.5196 1.0579
Gne glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase 0.2860 -1.0808
Gene symbol, gene description, p value and fold change of Mgat2 deficient CD4+ T cells relative to control are shown. The microarray confirms loss of
Mgat2 expression, highlighted in bold.
DOI: 10.7554/eLife.14814.013
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Table 2. List of the top 50 differentially expressed genes.
Gene symbol Gene description p Value Fold change
Rpl36al ribosomal protein L36A-like 4.44E-16 -15.6258
Mgat2 mannoside acetylglucosaminyltransferase 2 9.43E-14 -27.8780
Fn1 fibronectin 1 5.83E-12 -7.5845
Cpm carboxypeptidase M 3.54E-10 3.1233
Zbtb16 zinc finger and BTB domain containing 16 5.45E-10 -3.3239
Mmp9 matrix metallopeptidase 9 1.58E-09 -3.9658
Serpinb10-ps serine (or cysteine) peptidase inhibitor, clade B (ovalbumin), member 10, pseudogene 4.39E-09 -5.0634
Zfp69 zinc finger protein 69 4.63E-09 -2.1283
Cd93 CD93 antigen 1.04E-08 -2.3236
Atp8a2 ATPase, aminophospholipid transporter-like, class I, type 8A, member 2 2.64E-08 -2.2711
Gpr141 G protein-coupled receptor 141 3.83E-08 -3.4035
Penk preproenkephalin 5.28E-08 3.8411
Clec7a C-type lectin domain family 7, member a 8.21E-08 -2.4336
Lyz1 lysozyme 1 1.06E-07 -3.4287
Mpeg1 macrophage expressed gene 1 1.18E-07 -4.3408
Klra2 killer cell lectin-like receptor, subfamily A, member 2 1.33E-07 -4.4037
Kit kit oncogene 2.44E-07 -2.3150
Plbd1 phospholipase B domain containing 1 2.47E-07 -2.9529
Lyz2 lysozyme 2 2.83E-07 -3.6156
Pld4 phospholipase D family, member 4 3.00E-07 -4.1375
Ace angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 3.36E-07 -3.3758
Sirpa signal-regulatory protein alpha 3.40E-07 -3.9975
Clec12a C-type lectin domain family 12, member a 3.54E-07 -4.4547
Tlr13 toll-like receptor 13 4.15E-07 -6.5477
Tnfrsf21 tumor necrosis factor receptor superfamily, member 21 4.86E-07 -3.4333
Tgfbi transforming growth factor, beta induced 5.57E-07 -3.6315
Adrbk2 adrenergic receptor kinase, beta 2 5.98E-07 -2.0416
Il12rb2 interleukin 12 receptor, beta 2 7.32E-07 -2.6927
Csf1r colony stimulating factor 1 receptor 7.57E-07 -5.9870
Xcl1 chemokine (C motif) ligand 1 9.55E-07 -2.0969
Mlh1 mutL homolog 1 (E. coli) 9.66E-07 -2.0854
Sulf2 sulfatase 2 1.01E-06 -2.9791
Igsf6 immunoglobulin superfamily, member 6 1.04E-06 -3.0615
Gpr56 G protein-coupled receptor 56 1.10E-06 -2.2352
Fcna ficolin A 1.23E-06 -4.7706
Clec4a1 C-type lectin domain family 4, member a1 1.29E-06 -5.5202
Gm11428 predicted gene 11428 1.33E-06 -2.5636
Kcnj16 potassium inwardly-rectifying channel, subfamily J, member 16 1.35E-06 -2.5828
Coro2a coronin, actin binding protein 2A 1.80E-06 1.5820
Clec4a3 C-type lectin domain family 4, member a13 1.88E-06 -4.7329
Muc13 mucin 13, epithelial transmembrane 1.91E-06 -2.0524
Abcd2 ATP-binding cassette, sub-family D (ALD), member 2 2.49E-06 -2.2046
Cd68 CD68 antigen 2.56E-06 -2.6229
Cd34 CD34 antigen 2.65E-06 -1.9429
Table 2 continued on next page
Mkhikian et al. eLife 2016;5:e14814. DOI: 10.7554/eLife.14814 13 of 27
Research article Biochemistry Cell biology
trans Golgi compartment. To further evaluate this hypothesis, we examined the subcellular localiza-
tion of the three UDP-GlcNAc Golgi transporters (SLC35A3, SLC35B4, and SLC35D2) and B3GNT2.
Jurkat T cells were transfected with DDK or HA tagged versions of these proteins and examined for
intra-Golgi localization using confocal microscopy-based line scan analysis. Intra-Golgi localization
was determined by co-staining transfected cells with the cis and trans markers GM130 and TGN46,
respectively, and determining the peak intensity of fluorescence along a line scan relative to these
markers (Dejgaard et al., 2007). All three UDP-GlcNAc transporters localized to the cis and medial
Golgi compartments while B3GNT2 localized to a later Golgi compartment (Figure 5A–E). In addi-
tion, overexpression of the UDP-GlcNAc transporters did not drive poly-LacNAc production
(Figure 5F). These results suggest that the trans Golgi is comparatively deficient in UDP-GlcNAc,
thereby limiting B3GNT activity and poly-LacNAc extension under steady state conditions.
As B3GNT requires UDP-GlcNAc to generate poly-LacNAc, we reasoned that these two factors
must co-localize to drive homeostatic up-regulation of poly-LacNAc following disruption of branch-
ing activity. Co-localization may arise from movement of UDP-GlcNAc transporters to the trans Golgi
and/or movement of B3GNT to the medial Golgi. However, SW treatment did not alter the Golgi
localization of the three UDP-GlcNAc transporters or B3GNT2, arguing against this possibility
(Figure 5E and Figure 5—figure supplement 1A–D). Alternatively, UDP-GlcNAc may directly shift
from the medial to trans Golgi via the inter-cisternal transport system. Significant loss of activity of
medial Golgi branching enzymes should acutely raise UDP-GlcNAc levels within the medial Golgi,
with excess UDP-GlcNAc subsequently moving forward to the trans Golgi via inter-cisternal diffusion.
Measuring UDP-GlcNAc by LC-MS/MS in a whole cell vesicular fraction isolated from post nuclear
supernatant revealed significant levels of UDP-GlcNAc (Figure 6—figure supplement 1A–B). To
ensure that UDP-GlcNAc was indeed within the vesicles as opposed to merely associated with the
outer membrane, the post nuclear supernatant (PNS) was treated with either 0.1% Triton-X or
50 mM uridine monophosphate (UMP) for 15 min prior to isolation of the vesicular fraction by ultra-
centrifugation. Both treatments significantly reduced the amount of UDP-GlcNAc in the vesicular
fraction, confirming UDP-GlcNAc was located in vesicles containing UDP-GlcNAc/UMP anti-porters
(Figure 6—figure supplement 1B–D).
To evaluate the effects of reduced branching activity in the medial Golgi, we compared Jurkat T
cells treated with and without kifunensine. Consistent with our hypothesis, UDP-GlcNAc levels were
elevated in the vesicular but not the cytosolic fractions of kifunensine treated Jurkat T cells
(Figure 6A). To examine the Golgi directly, we used antibodies to the trans marker TGN46 to
immuno-isolate a Golgi enriched fraction from Jurkat T cell PNS. As expected from the physical con-
nections between Golgi cisterna, western blotting for cis, medial, and trans Golgi markers confirmed
that all three cisternal compartments were recovered with anti-TGN46 (Figure 6B). UDP-GlcNAc
was elevated in the Golgi of kifunensine treated Jurkat T cells despite no difference in total cellular
or cytosolic UDP-GlcNAc levels (Figures 4G,6A,C). Finally, we isolated a fraction enriched for trans-
Golgi network (TGN) vesicles from Jurkat T cells by pretreating with Brefeldin A prior to pull down
with anti-TGN46. Brefeldin A separates the trans-Golgi network from the rest of the Golgi by fusing
the latter with the endoplasmic reticulum (Martı´nez-Alonso et al., 2013). TGN46 immuno-isolated
vesicles from Brefeldin A treated Jurkat T cells were partially depleted for cis and medial Golgi
markers relative to trans Golgi markers including B3GNT2, confirming relative enrichment of the
Table 2 continued
Gene symbol Gene description p Value Fold change
Cxcr6 Sigmachemokine (C-X-C motif) receptor 6 2.68E-06 -3.3244
Mpo myeloperoxidase 2.80E-06 -15.0742
Car1 carbonic anhydrase 1 2.95E-06 -10.5252
Pira11 paired-Ig-like receptor A11 3.03E-06 -3.3245
Emr1 EGF-like module containing, mucin-like, hormone receptor-like sequence 1 3.18E-06 -6.1010
Pira1 paired-Ig-like receptor A1 3.23E-06 -3.6538
Gene symbol, gene description, p value and fold change of Mgat2 deficient CD4+ T cells relative to control are shown. Data are ordered by p value.
DOI: 10.7554/eLife.14814.014
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Figure 5. The UDP-GlcNAc transporters are localized to an earlier Golgi compartment than B3GNT2. (A–D) Jurkat T cells were transfected with
plasmids containing B3GNT2-HA (A), SLC35A3-DDK (B), SLC35B4-DDK (C), or SLC35D2-DDK (D), cultured for 24 hr and then stained for GM130
Figure 5 continued on next page
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trans/TGN compartment (Figure 6D and E). Vesicles from kifunensine treated Jurkat T cells demon-
strated increased UDP-GlcNAc relative to control (Figure 6F), indicating that UDP-GlcNAc levels
rise in the trans Golgi when medial Golgi branching activity is significantly diminished.
Although the mechanism for cargo transport between Golgi cisterna is incompletely understood,
the prevailing model is cisternal maturation, where entire cisterna move forward with their cargo,
while Golgi enzymes/transporters are pulled back to earlier cisterna by vesicular transport (Glick and
Luini, 2011). However, this model has recently been expanded by data suggesting that small cargo
transits the Golgi by diffusion via inter-cisternal tubules that vertically connect the cis, medial, and
trans compartments (Martı´nez-Alonso et al., 2013; Beznoussenko et al., 2014; Trucco et al.,
2004). Indeed, at least in CHO cells, there is evidence for functional continuity throughout sub-com-
partments of the Golgi (Kim et al., 2001). Golgi stacks, consisting of the cis, medial, and trans com-
partments, are also connected longitudinally to other Golgi stacks by tubules. Nocodazole, which
interrupts longitudinal but not vertical Golgi tubules, had no effect on poly-LacNAc induction by SW
in Jurkat T cells (Figure 6G). In contrast, pyrrophenone disrupts both longitudinal and inter-cisternal
vertical tubules via inhibition of cytosolic phospholipase A2-a (San Pietro et al., 2009). Pyrrophe-
none significantly blocked SW induced up-regulation of poly-LacNAc in Jurkat T cells in a dose
dependent manner, as indicated by comparing its effects on LEA and ConA staining; the latter con-
trolling for any changes in Golgi transport (Figure 6H and Figure 6—figure supplement 1E). In con-
trast, pyrrophenone had no effect on ConA, LEA, or L-PHA levels in control Jurkat T cells lacking SW
(Figure 6—supplement figure 1F–H). We conclude that when branching enzymes under-utilize
UDP-GlcNAc in the medial Golgi, UDP-GlcNAc accumulates and then shifts by diffusion to the trans
Golgi via inter-cisternal tubules, thereby increasing substrate supply to B3GNT and triggering poly-
LacNAc extension (Figure 7). However, our data do not exclude additional transfer of UDP-GlcNAc
via vesicles or by cisternal maturation.
Discussion
Our data demonstrates that structurally disparate glycans are functionally equivalent based on Lac-
NAc content and suggests a novel self-correcting mechanism in the Golgi that sustains cellular
homeostasis by ensuring LacNAc content is maintained at a minimal level within N-glycans. The com-
plexity of glycan structures provides tremendous challenges for discerning the functional role of gly-
cans in biology. Although N-glycan structures are highly diverse, redundancy of structural motifs
within individual glycans has previously received little consideration as a means to collapse complex-
ity and decipher glycan information. Deficiency of glycosylation pathway genes often give rise to
new and unusual structures, triggering some to suggest that these may represent compensatory
structures (Stone et al., 2009; Takamatsu et al., 2010; Ismail et al., 2011; Dam and Brewer, 2010;
Dennis and Brewer, 2013). However, proof of functional equivalency has largely been lacking. The
similar degree of hyperactivity between Mgat5 and Mgat2 deficient T cells indicates that poly-Lac-
NAc extended hybrid structures are functionally equivalent to complex tri-antennary structures.
Importantly, blockade of mannosidase II and Mgat2 deficiency produced a similar phenotype, which
was blocked/reversed by both mannosidase I inhibition and Mgat1 deficiency, despite each target-
ing distinct biochemical steps and resulting in distinct structures. Thus, our data demonstrate that
Figure 5 continued
(green), TGN46 (blue) and either anti-HA (A) or anti-DDK (B–D) in red. Shown are representative confocal slices from transfected cells. The white arrows
demonstrate areas deemed suitable for line scan analysis and the histograms (far right) demonstrate signal intensities along the line scans. DAPI
staining is shown in grey scale. (E) Average localizations of the indicated Golgi proteins in Jurkat T cells treated with and without swainsonine (see
Figure 5—figure supplement 1) relative to GM130 (cis) and TGN46 (trans) markers. Error bars show standard deviation. (F) Jurkat cells were
transfected with mVenus alone or in combination with the four constructs of interest. After 48 hr, cells were analyzed for LEA binding by flow cytometry
gating on mVenus- and mVenus+ cells as indicated. NS, not significant; *p<0.05; **p<0.01; ***p<0.001 (unpaired two-tailed t-test with Welch’s (E and F)
and Bonferroni correction (E)). Data show images and histograms from representative cells (A–D), or pooled analysis from 30–40 cells per condition (E).
Error bars indicate mean ± S.D. (E) or mean ± s.e.m (F).
DOI: 10.7554/eLife.14814.015
The following figure supplement is available for figure 5:
Figure supplement 1. Branching deficiency does not cause relocalization of the UDP-GlcNAc transporters or B3GNT2.
DOI: 10.7554/eLife.14814.016
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Figure 6. Intra-Golgi UDP-GlcNAc shifts to later Golgi compartments when use in the medial Golgi is inhibited. (A) LC-MS/MS quantitation of UDP-
GlcNAc in post-nuclear supernatants (PNS), vesicular, and cytosolic fractions of kifunensine treated and untreated Jurkat T cells. (B) PNS (input) from
kifunensine treated and untreated Jurkat T cells was used for Golgi enrichment via anti-TGN46 immuno-isolation followed by blotting for the Golgi
compartment markers GM130 (cis), GS27 (medial/trans), and Syntaxin6 (trans). (C) LC-MS/MS quantitation of UDP-GlcNAc in anti-TGN46 bound and
unbound fractions from kifunensine treated and untreated Jurkat T cell PNS. (D) PNS of Jurkat T cells treated for 0, 15, and 30 min with the Golgi
disruptor Brefeldin A were used for anti-TGN46 immuno-isolation followed by blotting for B3GNT2 and the GM130 (cis), GS28 (cis/medial), and TGN46
Figure 6 continued on next page
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structurally diverse glycans are biologically equivalent if they share a similar amount of LacNAc. The
overall glycan structure sets the total LacNAc content, thereby largely determining avidity of binding
for galectins. It should be noted however, that although these differing glycoforms are clearly
Figure 6 continued
(trans) Golgi markers. (E) Quantitation of D, (F) LC-MS/MS quantitation of UDP-GlcNAc in anti-TGN46 immuno-isolates from Jurkat cells treated with
Brefeldin A for 15 min. (G) LEA flow cytometric analysis of Jurkat T cells pre-treated with nocodazole where indicated for 45 min, followed by
swainsonine where indicated for 5 hr. (H) Jurkat T cells that were treated with nocodazole +/- pyrrophenone as indicated for 45 min were treated with
or without swainsonine for 5 hr and then analyzed for LEA and ConA binding by flow cytometry. Shown is the ratio of LEA MFI to ConA MFI for each
condition. NS, not significant; *p<0.05; **p<0.01; ***p<0.001; (unpaired one-tailed (A, C, F and G) or two-tailed (H) t-test with Welch’s correction and
Bonferroni correction (H)). Data show one experiment representative of at least three independent experiments except F which shows combined data
from two independent experiments. Error bars indicate mean ± s.e.m.
DOI: 10.7554/eLife.14814.017
The following figure supplement is available for figure 6:
Figure supplement 1. Intra-Golgi UDP-GlcNAc shifts to later Golgi compartments when use in the medial Golgi is inhibited.
DOI: 10.7554/eLife.14814.018
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Figure 7. Model of an inherent Golgi self-correcting mechanism to maintain LacNAc homeostasis. The majority of UDP-GlcNAc entering the Golgi is
supplied to its early compartments by the UDP-GlcNAc/UMP antiporters, which are preferentially localized to the cis/medial Golgi. Under branching
proficient conditions (A), UDP-GlcNAc is used by the branching enzymes MGAT1, 2, 4, and 5, with little unused UDP-GlcNAc supplying the poly-
LacNAc synthesizing B3GNT enzymes. The resulting array of N-glycans produced thus contains more LacNAc branches than linear LacNAc polymers
(A). When the branching pathway is disrupted (B), or presumably the Golgi is otherwise stressed, leading to reduced UDP-GlcNAc usage in the medial
Golgi, UDP-GlcNAc is driven forward (at least partially through intercisternal tubules) and promotes production of bioequivalent poly-LacNAc
containing glycans by the trans Golgi-resident B3GNT family of enzymes. Under this scenario, loss of LacNAc branches is balanced by increased
production of linear LacNAc polymers, a self-correcting ability that serves to maintain cell surface LacNAc density and thus the galectin-glycoprotein
lattice (A). In the context of T cells, this homeostatic mechanism acts to curtail catastrophic T cell hyperactivity and promotes self-tolerance.
DOI: 10.7554/eLife.14814.019
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overlapping, they might not be strictly identical due to distinct geometries of LacNAc presentation
or modification by fucose or sialic acid.
Our data support a model of N-glycosylation that emphasizes the significance of functional units
within an N-glycan, such as LacNAc groups, rather than uniqueness of the overall glycan structure in
determining biological function. The National Academy of Sciences position paper on Glycoscience
has proposed a major focus on glycan structural determination (National Academy of Sciences,
2012). Our data suggests that glycan diversity may be collapsed into a much smaller group of bio-
equivalent structures based on the number of structural subunits within the overall glycan that bind
to a given animal lectin. Indeed, it may be possible that through further studies exploring bioequiva-
lence among glycans, a glycan code can be deciphered based on interaction with animal lectins.
Such an approach may greatly alleviate the complexity in determining structure-function relation-
ships and relevance to human health.
Essential biological systems employ homeostatic mechanisms to maintain cellular integrity. N-
-glycosylation is an essential biosynthetic pathway necessary for cellular homeostasis and mammalian
development (Dennis et al., 2009), yet lacks a known self-correcting mechanism. Our data suggest
that homeostatic control of LacNAc content does not result from changes in enzyme levels/activity
or metabolic production of UDP-GlcNAc substrate; but rather appears to arise from the structure of
the Golgi. A defining feature of the Golgi is its polarized compartmentalization, with a cis to trans
organization. Glycosylation enzymes are arranged along the Golgi roughly in the order in which they
act. Why the Golgi has evolved this organization remains an open question. Our data indicate that
the UDP-GlcNAc transporters preferentially supply UDP-GlcNAc to the cis/medial over trans Golgi,
thus prioritizing branching over extension. Despite the presence of continuities between Golgi cis-
terna and previous work arguing that the Golgi is functionally interconnected (Kim et al., 2001), our
data suggest that the segmented organization of enzymes and transporters allows for local deple-
tion of substrate prior to diffusion to other compartments. In this manner, the evolutionary place-
ment of the B3GNT poly-LacNAc extension enzymes in the trans Golgi provides a backup
mechanism that captures unused UDP-GlcNAc from the medial Golgi shunted via inter-cisternal
tubules. This backup system may also explain the lack of evolutionary pressure to produce genetic
redundancy in the Golgi branching enzymes in mammals and the dramatically more severe pheno-
type seen with Mgat1 deficiency, which blocks all production of N-glycan LacNAc, compared to
other Mgat genes (Ioffe and Stanley, 1994; Metzler et al., 1994).
The Golgi is charged with maintaining the integrity of the glycome/lattice or risking disease.
Thus, fidelity of glycan biosynthesis must be maintained under a variety of cellular states and be
active virtually at all times. High protein transit rates present a significant challenge to the Golgi and
have the potential to reduce the medial Golgi branching efficiency by decreasing the time available
for branching reactions. Under this scenario, having a back-up system that provides poly-LacNAc
extension in the trans Golgi by capturing unused UDP-GlcNAc from the medial Golgi would be criti-
cal for the maintenance of the lattice at a minimal essential level. Even in an unstressed system, a
second step in the assembly line would act to counteract the moment to moment variability and sto-
chastic uncertainty of glycan synthesis. Severe branching deficiency (induced by SW treatment or
Mgat2 deletion) uncovers this continual process. Such a mechanism is akin to DNA repair, which is
occurring all of the time but made more apparent in the context of physiological or external stress.
A clear understanding of the network of interacting factors that coalesce to determine the state
of the galectin-glycoprotein lattice is required for the successful exploitation of its therapeutic
potential. Interventions must be able to overcome or at least take into account the homeostatic cel-
lular response to the initial disturbance. For example, the effectiveness of SW as an anti-cancer ther-
apeutic is likely limited by compensatory poly-LacNAc production (Goss et al., 1994; 1997). Thus,
therapeutic strategies aimed at disrupting the lattice should block branching and extension simulta-
neously, or target a more proximal regulator such as UDP-GlcNAc metabolism or transport. In light
of these considerations, the lattice approach to cancer treatment may merit re-visitation. Conversely,
a deeper knowledge of the central regulatory machinery that determines total LacNAc content will
also be required for therapeutic approaches that seek to strengthen the lattice.
The presence of functional groups (LacNAc) as subcomponents of glycans, combined with our
current understanding of Golgi transport, may also explain the curious use of three different nucleo-
tides to charge the array of sugars used as substrate donors for glycosylation. These sugar-nucleoti-
des are transported into the Golgi via an anti-port mechanism where cytosolic sugar-nucleotides are
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exchanged for Golgi nucleotides generated by the action of glycosyltransferase enzymes. Increased
availability and use of UDP-GlcNAc in the trans Golgi would increase uridine-monophosphate (UMP)
levels, thereby driving anti-port of UDP-Galactose into the trans Golgi to promote further extension
with poly-LacNAc rather than capping by sialic acid. Were sialic acid also charged with UDP rather
than cytidine-monophosphate (CMP), UDP-GlcNAc usage in the trans Golgi would drive import of
UDP-Sialic acid and capping equally with UDP-Galactose and extension.
Materials and methods
Galectin-3 binding
Recombinant mouse galectin-3 (R&D Systems, Minneapolis, MN) was labeled using an Alexa Fluor
488 protein labeling kit (ThermoFisher Scientific, Waltham, MA). Cells were stained for flow cytome-
try using 3 mg labeled galectin-3 per test. Staining was carried out for 30 min at room temperature
followed by one wash and fixation with paraformaldehyde. For the lactose control samples, 50 mM
lactose was included in all steps.
PNGase F treatment of live cells
Purified mouse T cells were washed twice in HBSS and resuspended in 100 ul of G7 reaction buffer.
2500 units of glycerol free PNGase F (New England Biolabs, Ipswich, MA) was added to the cells
and the reaction was allowed to proceed for up to four hours at 37 degrees Celsius. Cells were then
washed with HBSS and immediately stained for flow cytometry.
MALDI-TOF mass spectrometry
Control and SW treated Jurkat T cells were homogenized by sonication in 25 mM Tris, 150 mM
NaCl, 5 mM EDTA, and 1% CHAPS, pH 7.4, dialyzed, reduced, and carboxymethylated, digested
with trypsin to generate glycopeptides and treated with PNGase F (Roche, Basel, Switzerland) to
release N-glycans. N-glycans were digested by endo-b-galactosidase (AMS Biotechnology) or Siali-
dase A (Prozyme, Hayward, CA) prior to permethylation and mass spectrometry analysis.
Cell lines
Human Jurkat cell line E6-1 and its derivative cell lines with deficiency in TCRb (J.RT3-T3.5), and Lck
(J.CaM1.6) were purchased from ATCC. Two separate lots of E6-1 Jurkat cells were purchase
throughout the study and found to be equivalent in LEA increase in response to SW treatment. Cells
were cultured, expanded and frozen down to create low passage stocks. These were subsequently
thawed and used for experiments, limiting usage to a maximum of ten passages. They were grown
in RPMI 1640 medium with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin/strepto-
mycin and 2 mM 2-mercaptoethanol. CFPAC-1, CHO, Lec1, Raji, RPMI 8226, RS4; 11 and Kasumi-1
cell lines were also purchased from the ATCC. BJ, HT-29 and HEK-293 cells were a kind gift from
Bogi Andersen. MCF-7 and Hela cells were a kind gift from Marian Waterman. Mouse postnatal day
1 neural stem cells were a kind gift from Thomas Lane. HUVEC cells were a kind gift from Christo-
pher Hughes, and K562 cells were a kind gift from David Fruman. No routine mycoplasma testing or
identity authentication was performed.
Reagents, mice and flow cytometry
Isolated human CD3+ T cells purified by negative selection (RosetteSep, StemCell
Technologies, Vancouver, Canada) were stimulated with plate-bound anti-CD3 (OKT3, eBioscience,
San Diego, CA). Procedures with human subjects were approved by the Institutional Review Board
of the University of California, Irvine. Mgat2f/f (006892), Mgat1f/f (006891) and Lck-Cre (003802) mice
were obtained from Jackson Laboratory. B3gnt2+/- (11605) embryos were from the MMRRC and
were rederived by the UC Irvine Transgenic Mouse Facility. Inter-breeding generated all other mice.
Mice were selected randomly for experiments and approved by the Institutional Animal Care and
Use Committee of the University of California, Irvine. Human cells were stained with anti-CD4, anti-
CD69 (eBioscience) and/or L-PHA-FITC (Phaseolus Vulgaris Leukoagglutinin, Vector
Labs, Burlingame, CA). Mouse cells were stained with anti-CD4 (RM 4–5), anti-CD8 (53–6.7), and
anti-CD69 (H1.2F3) (eBioscience). Proliferation was assessed by 5, 6-carboxyfluorescein diacetate
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succinimidyl ester (CFSE; ThermoFisher Scientific) at 1 uM in PBS (20 min., 4˚C) and stimulated with
plate-bound anti-CD3e. Cells were cultured in RPMI-1640 media supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 100 U/ml penicillin/streptomycin and 2 mM 2-mercaptoethanol.
Where indicated, 40 mM GlcNAc (Ultimate Glucosamine, Wellesley Therapeutics
Inc., Toronto, Canada) and 10 mM uridine (Sigma-Aldrich, St Louis, MO) were added to cells in cul-
ture at time 0. For flow cytometric analysis of glycan expression, cells were stained with 2 mg/ml
L-PHA-FITC, ConA-FITC, LEA-FITC or biotinylated versions of these lectins followed by DyLight649
labeled streptavidin (Vector Labs). Staining was carried out as previously described (Lee et al.,
2007; Grigorian et al., 2007). Flow cytometry experiments were performed with the BD FACSCali-
bur, LSR II, or Attune Acoustic Focusing Cytometer. Data analysis was performed using FlowJo
software.
RNA isolation and microarray
CD4+ T cells isolated from Mgat2f/f mice and L-PHA-CD4+ T cells isolated from Mgat2f/f::Lck-Cre+
mice were used for analysis. The RNeasy mini kit (Qiagen, Valencia, CA) was used for RNA extrac-
tion. Gene expression was assessed using the Affymetrix Mouse Gene 1.0 ST arrays in triplicate.
Array data were quantified with Expression Console version 1.1 software (Affymetrix,
Santa Clara, CA) using the PLIER Algorithm default values. Expression values were then filtered as
present/absent at expression 100. The Cyber-T web server was used for data analysis and to com-
pare samples.
Enzymatic assays
B3GNT enzyme activity was measured using a glycosyltransferase activity kit (R&D systems). Five mil-
lion Jurkat cells grown with or without SW were washed three times with Tris buffered saline and
lysed with 300 ml of lysis buffer (10 mM Tris pH 7.5, 2 mM MnCl2, 4 mM CaCl2, 0.5% Triton-X, with
protease inhibitors). The lysate was cleared of insoluble material by centrifugation and dialyzed over-
night in an identical solution to remove cellular phosphate. Enzyme activity was measured following
the instructions of the kit. Briefly, 25 ml of lysate was mixed with 25 ml of reaction mixture to give a
final concentration of 6 mM N-acetyllactosamine, 5 mM UDP-GlcNAc, and 6 ng/ml coupling phos-
phatase. The reaction was allowed to proceed for two hours at 37˚C, followed by visualization of
released phosphate by a malachite green reagent as indicated in the kit. Absorbance at 620 nm was
determined using a plate reader and converted using a phosphate standard run in parallel. Back-
ground was determined and subtracted by parallel reactions that lacked the specific acceptor N-
-acetyllactosamine but contained UDP-GlcNAc and coupling phosphatase.
Experimental autoimmune encephalomyelitis
EAE was induced by subcutaneous immunization of randomly selected female mice at days 0 with
100 mg of bovine MOG35-55 (AnaSpec, Fremont, CA) emulsified in Complete Freund’s Adjuvant
containing 4 mg/ml heat-inactivated Mycobacterium tuberculosis (H37RA; Difco). On days 0 and 2,
mice received 150 ng of pertussis toxin (List Biological Laboratories, Campbell, CA) by intraperito-
neal injection. Mice were examined daily for clinical signs of EAE over the next 30 days with observer
blinded to treatment conditions. Mice were scored daily as follows: 0, no disease; 1, loss of tail tone;
2, hindlimb weakness; 3, hindlimb paralysis; 4, forelimb weakness or paralysis and hindlimb paralysis;
5, moribund or dead. Kifunensine was given orally via the drinking water at 0.2 mg/ml for 8 days
starting 3 days before immunization. All mice were housed with 12 hr light/dark cycles.
Spectrophotometric measurement of UDP-GlcNAc
UDP-GlcNAc was measured spectrophotometrically as previously described (Barthel et al., 2011).
Briefly, Jurkat cells were grown in various conditions, washed thoroughly with PBS and pelleted at
50  106 cells per 1.5 ml tube. Cells were lysed by addition of 200 ml of chloroform/water (1:1), vor-
texed for 2 min and centrifuged at 15,000  g for 20 min at 4˚C. The aqueous phase was transferred
to a fresh tube and 10 ml of 1 N HCl was added to hydrolyze UDP-GlcNAc to GlcNAc. After heating
for 20 min at 80˚C, the sample was neutralized with 10 ml 1 N KOH. Next, 50 ml of 200 mM potas-
sium tetraborate (Sigma-Aldrich) was added, and the sample was heated at 80˚C for 25 min and
then cooled on ice for 5 min. 150 ml of Ehrlich’s reagent (Sigma-Aldrich) (diluted 1:2 in acetic acid)
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was added to the sample, mixed, and incubated for 20 min at 37˚C. The sample was centrifuged at
15,000  g for 20 min, 200 ml were added to a 96-well plate, and the absorbance was measured at
595 nm. Absorbance was converted to UDP-GlcNAc concentration by comparing to a GlcNAc stan-
dard curve run simultaneously.
UDP-GlcNAc measurement by LC-MS/MS
Jurkat and mouse T cells were treated as described in the text, then harvested, washed twice with
ice-cold 1x PBS and counted. After normalizing for cell number, cells were pelleted in 1.5 ml Eppen-
dorf tubes by centrifuging at 350 g for 7 min at 4˚C. Metabolites were extracted from the pellets by
the addition of 1 ml of ice-cold solution of 40% acetonitrile, 40% methanol, and 20% water. The
tubes were vortexed for 1 hr at 4˚C and spun down at 14000 rpm for 10 min at 4˚C (Eppendorf,
Hamburg, Germany). The supernatant was transferred to fresh tubes and evaporated to dryness in
an Eppendorf Vacufuge at 30˚C (Eppendorf). The dry samples were stored at -80˚C until analysis at
which point they were reconstituted in 100 ml of LC-MS grade water and centrifuged again at
14000 rpm for 10 min at 4˚C. The supernatants were carefully transferred to fresh tubes to be ana-
lyzed by mass spectrometry. The instrument used was a Waters Quattro Premier XE LC-MS/MS
(Manchester, UK) equipped with ultra-performance liquid chromatography (UPLC) and a refrigerated
autosampler. The separation was performed on BEH C18 reversed phase column (Waters, Manches-
ter, UK) with a mobile phase A containing LC-MS grade water (JT Baker) modified with 0.2% Acetic
Acid, 2% Acetonitrile and 5 mM Ammonium Acetate while mobile B containing LC-MS grade Aceto-
nitrile (JT Baker) modified with 0.2% Acetic Acid and 5 mM ammonium Acetate. The gradient was
performed with a 1 min ramp from 2% mobile B to 90%, which was then kept at 90% for 1 more min-
ute and ramped back to 2% for column equilibration. The mass spectrometry measurement was per-
formed in negative mode where the parent ion and fragment ion were measured simultaneously to
be used for quantitation of the metabolites. A standard curve was generated using UDP-GlcNAc
(Sigma-Aldrich), which was used for the quantitation of the metabolites produced by the cells.
Cellular subfractionation and Golgi immunoisolation
Jurkat cells were grown with or without kifunensine for four days, or until cultures reached a density
between 1.5–2 x 106 cells/ml. Cells used for Golgi compartment disruption were treated with 1000x
Brefeldin A (eBioscience 00-4506-51) for up to 30 min. Cells were washed with HEPES buffered
saline (145 mM NaCl, 100 mM HEPES, pH 7.4) and incubated in an ice-cold hypotonic solution
(30 mM KCl, 3 mM MgOAc, 2 mM DTT, 20 mM HEPES, pH 7.5) for 5 min on ice. The volume of the
hypotonic solution used was 2.5 times the volume of the cell pellet. The cell solution was then
passed through a 26.5 gauge syringe five times before a 1/10 volume of ice-cold hypertonic solution
(375 mM KCl, 22.5 mM MgOAc, 1 mM DTT, 220 mM HEPES, pH 7.5) was added. The solution was
centrifuged twice in succession at 1000x g for 5 min each to pellet cells and nuclei. The post-nuclear
supernatant (PNS) was carefully transferred to a new tube and processed further. Ultracentrifugation
of the PNS at 100,000 g for 30 min yielded a vesicular fraction (the pellet) and a cytosolic fraction
(the supernatant). For immunoisolation experiments, PNS was incubated with anti-TNG46 antibody
(Sigma-Aldrich T7576-200UL) previously conjugated to Protein G Dynabeads (ThermoFisher Scien-
tific) for 30 min at 4˚C with tumbling. Supernatant was removed, and immunoisolated Golgi was
washed with HEPES buffered saline before processing for mass spectrometry or immunoblot
analysis.
Plasmids, transfection and microscopy
DNA encoding mVenus and human B3GNT2 (HA tagged at the C terminus) were codon-optimized
for human expression, synthesized, and cloned into the pmax Cloning vector
(Lonza, Basel, Switzerland). Myc-DDK tagged human SLC35A3 (RC215108), SLC35B4 (RC203263),
and SLC35D2 (RC218472) cDNA clones were purchased from Origene (Rockville, MD) in pCMV6
expression vectors. Cells were transfected with each construct individually (for microscopy) or in
combination with mVenus to label transfected cells (for flow cytometry). 106 cells were transfected
with 4–8 mg of DNA using an Amaxa Nucleofector IIb set to program G-10. Cells were immediately
transferred to pre-equilibrated media in 6 well plates and placed in the tissue culture incubator.
After 5 hr, media was changed and pharmacological treatments were started. For localization
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studies, cells were transferred to poly-L-lysine coated chamber slides (Falcon) after 24–48 hr of treat-
ment. Cells were incubated in the chamber slides for 15 min to allow attachment to the slides and
then fixed for 1 hr with 4% paraformaldehyde in PBS. Standard immunocytochemical staining was
performed. Permeabilization was achieved with 0.1% saponin (Sigma-Aldrich). Primary antibodies
used were to GM130 (Clone 35, BD Biosciences, Franklin Lakes, NJ), TGN46 (AbD
Serotec, Hercules, CA), Mannosidase II (a kind gift from Dr. Christine Suetterlin), HA (ab9110,
Abcam, Cambridge, UK), and DDK (Clone 4C5, Origene). Slides were stained with the appropriate
secondary antibodies conjugated to Alexa Fluor (AF) 488, 555 and 647 and mounted with Prolong
Gold Antifade reagent with DAPI (ThermoFisher Scientific). GM130 and TGN46 were always visual-
ized with AF 488 and 647 respectively, while the protein of interest was visualized with AF 555.
Slides were imaged on a Zeiss LSM 780 confocal microscope using a Zeiss plan-apochromat 100x oil
objective with numerical aperture of 1.4. Localization of the proteins of interest was determined rela-
tive to GM130 and TGN46 using a line-scan method essentially identical to a previously published
report (Dejgaard et al., 2007). Briefly, 30–50 transfected cells were imaged per experimental condi-
tion. Files were coded to blind the analyzer to treatment and protein of interest. Images were
imported into the Zeiss Zen software (blue edition) with the AF 555 channel disabled. Line-scans (8–
10 pixels wide) were drawn perpendicular to the long axis on areas of the Golgi showing maximal
separation of GM130 and TGN46. Line-scans were used if they resulted in a single clearly discern-
able peak in all three channels. The relative distance of the peak intensity of the protein of interest
compared to the peak intensities of GM130 and TGN46 was then used to determine intra-Golgi
localization.
Immunoblotting
Immunoblotting was performed as described (Demetriou et al., 2001; Lee et al., 2007;
Grigorian et al., 2007). Antibodies against GM130 (610822), GS27 (611034), GS28 (611184), and
STX6 (610635) were from BD Biosciences. The TGN46 antibodies used for immunoisolation (T7576)
and immunoblotting (SAB4200235) were from Sigma, and the antibody against B3GNT2 was from
Origene (TA505283).
Statistical analysis
Statistics were calculated with Prism software (GraphPad). P values were from two- or one-tailed
unpaired t-tests (with Welch’s correction). The Bonferroni correction was applied to all multiple com-
parisons. No statistical method was used to predetermine sample size. The experiments were not
randomized.
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